

Resource Summary Report

Generated by [RRID](#) on Aug 4, 2026

YAP Antibody

RRID:AB_2218911

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 4912, RRID:AB_2218911

Antibody Information

URL: http://antibodyregistry.org/AB_2218911

Proper Citation: Cell Signaling Technology Cat# 4912, RRID:AB_2218911

Target Antigen: YAP

Host Organism: rabbit

Clonality: polyclonal

Comments: Applications: W, IP, IHC-P. Consolidation: AB_10694682.

Antibody Name: YAP Antibody

Description: This polyclonal targets YAP

Target Organism: monkey, rat, mouse, human

Defining Citation: [PMID:28486106](#)

Antibody ID: AB_2218911

Vendor: Cell Signaling Technology

Catalog Number: 4912

Alternative Catalog Numbers: 4912S

Record Creation Time: 20250820T044247+0000

Record Last Update: 20250820T194335+0000

Ratings and Alerts

No rating or validation information has been found for YAP Antibody.

No alerts have been found for YAP Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 59 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Guo W, et al. (2025) Mitochondrial CCN1 drives ferroptosis via fatty acid β -oxidation. *Developmental cell*, 60(17), 2294.

Stanland LJ, et al. (2025) A first-in-class EGFR-directed KRAS G12V selective inhibitor. *Cancer cell*.

Li G, et al. (2025) Microenvironmental β -TrCP negates amino acid transport to trigger CD8⁺ T cell exhaustion in human non-small cell lung cancer. *Cell reports*, 44(1), 115128.

Li S, et al. (2025) Glutamine synthetase modulates YAP activation by stabilizing LATS under glutamine homeostasis. *Cell reports*, 44(12), 116620.

Weaver MR, et al. (2025) The STRIPAK complex is required for radial sorting and laminin receptor expression in Schwann cells. *Cell reports*, 44(3), 115401.

Hu DJ, et al. (2025) Non-canonical Wnt signaling promotes epithelial fluidization in the repairing airway. *Nature communications*, 16(1), 4124.

Hsu HE, et al. (2025) Phosphoproteomics of osimertinib-tolerant persister cells reveals targetable kinase-substrate signatures. *Molecular systems biology*, 21(11), 1547.

McKenna CF, et al. (2024) Postabsorptive and postprandial myofibrillar protein synthesis rates at rest and after resistance exercise in women with postmenopause. *Journal of applied physiology (Bethesda, Md. : 1985)*, 136(6), 1388.

Hung CH, et al. (2024) Defective N-glycosylation of IL6 induces metastasis and tyrosine kinase inhibitor resistance in lung cancer. *Nature communications*, 15(1), 7885.

Naderi Yeganeh P, et al. (2024) Integrative pathway analysis across humans and 3D cellular models identifies the p38 MAPK-MK2 axis as a therapeutic target for Alzheimer's disease. *Neuron*.

Meyer NP, et al. (2024) Arp2/3 complex activity enables nuclear YAP for naïve pluripotency of human embryonic stem cells. *eLife*, 13.

Shiraishi K, et al. (2023) Biophysical forces mediated by respiration maintain lung alveolar epithelial cell fate. *Cell*, 186(7), 1478.

Ouyang H, et al. (2023) p120 RasGAP and ZO-2 are essential for Hippo signaling and tumor-suppressor function mediated by p190A RhoGAP. *Cell reports*, 42(12), 113486.

Chen L, et al. (2023) TGFB1 induces fetal reprogramming and enhances intestinal regeneration. *Cell stem cell*, 30(11), 1520.

Khampang S, et al. (2023) CRISPR/Cas9 mediated approach to generate YAP-depleted human embryonic stem cell line (MUS1e002-A-1). *Stem cell research*, 66, 102990.

Edwards W, et al. (2023) Quantitative proteomic profiling identifies global protein network dynamics in murine embryonic heart development. *Developmental cell*, 58(12), 1087.

Guo Y, et al. (2022) Opposing roles of ZEB1 in the cytoplasm and nucleus control cytoskeletal assembly and YAP1 activity. *Cell reports*, 41(1), 111452.

Baek SW, et al. (2022) YAP1 activation is associated with the progression and response to immunotherapy of non-muscle invasive bladder cancer. *EBioMedicine*, 81, 104092.

Kim M, et al. (2022) YAP1 and PRDM14 converge to promote cell survival and tumorigenesis. *Developmental cell*, 57(2), 212.

Elamin YY, et al. (2022) Pozitotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity. *Cancer cell*, 40(7), 754.